FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has completed a Korean Phase 1b/2a hearing-loss trial of its FAM19A5 antibody and continues dementia research alongside it.

  • Completion of the NS101 Phase 1b/2a hearing-loss trial was posted on ClinicalTrials.gov. Source
  • Published Alzheimer's mouse-model research in an international journal. Source

Roles often seen at this stageClinical & PV · Research & development · Data & AI

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Neuracle Science

Develops NS101, an antibody against the synapse-loss protein FAM19A5, for hearing loss, dementia and other neurological diseases.

NS101 (sudden sensorineural hearing loss)

Phase 2

A Korean Phase 1b/2a trial in sudden sensorineural hearing loss at 15 hospitals with 113 participants enrolled, now listed as completed on ClinicalTrials.gov.

NS101 (frontotemporal dementia)

Stage unconfirmed

An investigator-initiated trial in frontotemporal dementia, approved by Korea's Ministry of Food and Drug Safety in 2025.

NS101 (Alzheimer's disease)

Phase 1

Published results showing reversal of synapse loss and cognitive decline in Alzheimer's mouse models, and confirmed safety in a Phase 1a study of healthy adults in Canada.

Completion reported

Published a paper in Alzheimer's Research & Therapy showing that FAM19A5 inhibition reverses synapse loss and cognitive decline in Alzheimer's mouse models.

Completion reported

The NS101 Phase 1b/2a trial in sudden hearing loss was updated to completed on ClinicalTrials.gov.

Official role guide

Neuracle Science careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 뉴라클사이언스, 돌발성 난청 임상 완료…결과 공개 주목 ↗메디코파마 · Published 2026-11-03 · Sources checked 2026-11-18 · Original unavailable
  2. 뉴라클사이언스, FAM19A5 항체 알츠하이머병 인지 저하 회복 효능 입증 ↗더바이오 · Published 2025-07-23 · Sources checked 2026-11-18 · Original unavailable
  3. 뉴라클사이언스, 알츠하이머 치료 후보물질, 1a상 안전성 확인 ↗히트뉴스 · Published 2024-11-04 · Sources checked 2026-11-18 · Original unavailable